Treatment of anemia in myelofibrosis: focusing on Novel Therapeutic Options
Expert Opin Investig Drugs. 2023 Dec 10. doi: 10.1080/13543784.2023.2294324. Online ahead of print.ABSTRACTINTRODUCTION: Myelofibrosis is a clonal myeloproliferative neoplasm associated with the proliferation of hematopoietic stem cells, increased bone marrow fibrosis, extramedullary hematopoiesis, hepatosplenomegaly, abnormal cytokine production, and constitutional symptoms. These and many other factors contribute to the development of anemia in myelofibrosis patients.AREAS COVERED: This review summarizes novel and promising treatments for anemia in myelofibrosis including transforming growth factor-β inhibitors luspatercept and KER-050, JAK inhibitors momelotinib, pacritinib, and jaktinib, BET inhibitors pelabresib and ABBV-744, antifibrotic PRM-151, BCL2/BCL-XL inhibitor navitoclax, and telomerase inhibitor imetelstat.EXPERT OPINION: Standard approaches to treat myelofibrosis-related anemia have limited efficacy and are associated with toxicity. New drugs have shown positive results in myelofibrosis-associated anemia when used alone or in combination.PMID:38073183 | DOI:10.1080/13543784.2023.2294324
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Authors: Eren Arslan Davulcu Merve Beyza O ğuz Emre K ılıç Ahmet Emre E şkazan Source Type: research
More News: Anemia | Drugs & Pharmacology | Myeloproliferative Disorders | Stem Cell Therapy | Stem Cells | Toxicology